Virucidal activity of SARS-CoV-2 rapid antigen extraction buffers

https://doi.org/10.1016/j.jcv.2021.105062Get rights and content
Under a Creative Commons license
open access

Abstract

Since diagnostic sampling material must be considered as infectious, we evaluated whether extraction buffers of SARS-CoV-2 rapid antigen test kits may inactivate SARS-CoV-2. Of concern, seven of nine tested buffers lacked potent virucidal activity. To reduce risk of infection during assay performance, virucidal antigen extraction buffers that efficiently inactivate virus should replace the extraction buffers in these commercially available point-of-care devices.

Keywords

SARS-CoV-2 rapid antigen test
Point-of-care devices
Antigen extraction buffer
Assay safety
Virucidal buffer

Cited by (0)

1

These authors contributed equally to this article.

© 2021 The Author(s). Published by Elsevier B.V.